Abecma
(Idecabtagene vicleucel)Phase 2Cell therapy
Bristol-Myers SquibbThis medication is used to treat certain types of multiple myeloma (bone marrow cancer) that has returned or stopped responding to at least four previous treatments. It works by taking immune cells from the patient's own blood and modifying them to recognize and attack cancer cells.[1] Abecma is currently being investigated across 2 indications[3], with its most advanced program in Phase 2.[1]
Abecma is one of 64 cell therapy programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 2.
2
Indications
5
Total Trials
5
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Ninlaro
TakedaPreclinical
Abecma
Bristol-Myers SquibbPhase 2
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma4 trials
Show 1 more trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Idecabtagene vicleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- BCMA CAR-T[2]
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company